63.98
2.11%
+1.3212
Bio-Techne Corp stock is currently priced at $63.98, with a 24-hour trading volume of 286.41K.
It has seen a +2.11% increased in the last 24 hours and a -6.45% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $62.59 pivot point. If it approaches the $64.11 resistance level, significant changes may occur.
Previous Close:
$62.66
Open:
$62.83
24h Volume:
286.41K
Market Cap:
$10.03B
Revenue:
$1.14B
Net Income/Loss:
$224.16M
P/E Ratio:
42.09
EPS:
1.52
Net Cash Flow:
$225.39M
1W Performance:
+3.00%
1M Performance:
-6.45%
6M Performance:
+4.02%
1Y Performance:
-18.40%
Bio-Techne Corp Stock (TECH) Company Profile
Name
Bio-Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 McKinley Place NE, Minneapolis, MN
Bio-Techne Corp Stock (TECH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
Feb-02-24 | Downgrade | Stifel | Buy → Hold |
Dec-07-23 | Initiated | UBS | Buy |
Aug-28-23 | Initiated | William Blair | Outperform |
Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
Feb-23-21 | Upgrade | Stifel | Hold → Buy |
Jan-25-21 | Reiterated | The Benchmark Company | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
May-27-20 | Downgrade | Stifel | Buy → Hold |
May-14-20 | Initiated | The Benchmark Company | Buy |
Jan-08-20 | Resumed | Stephens | Overweight |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-02-19 | Upgrade | Janney | Neutral → Buy |
Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
Oct-17-18 | Initiated | Goldman | Neutral |
Jun-15-18 | Initiated | Argus | Buy |
Jul-13-17 | Initiated | Wells Fargo | Market Perform |
Feb-09-17 | Initiated | Citigroup | Buy |
Jan-18-17 | Initiated | Deutsche Bank | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio-Techne Corp Stock (TECH) Latest News
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks Investment Research
Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Navigating 4 Analyst Ratings For Bio-Techne
Benzinga
GSK or TECH: Which Is the Better Value Stock Right Now?
Zacks Investment Research
HRMY vs. TECH: Which Stock Is the Better Value Option?
Zacks Investment Research
Here's What Key Metrics Tell Us About Techne (TECH) Q2 Earnings
Zacks Investment Research
Bio-Techne Corp Stock (TECH) Financials Data
Bio-Techne Corp (TECH) Revenue 2024
TECH reported a revenue (TTM) of $1.14 billion for the quarter ending December 31, 2023, a +2.25% rise year-over-year.
Bio-Techne Corp (TECH) Net Income 2024
TECH net income (TTM) was $224.16 million for the quarter ending December 31, 2023, a -14.38% decrease year-over-year.
Bio-Techne Corp (TECH) Cash Flow 2024
TECH recorded a free cash flow (TTM) of $225.39 million for the quarter ending December 31, 2023, a -10.55% decrease year-over-year.
Bio-Techne Corp (TECH) Earnings per Share 2024
TECH earnings per share (TTM) was $1.38 for the quarter ending December 31, 2023, a -14.15% decline year-over-year.
Bio-Techne Corp Stock (TECH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Nusse Roeland | Director |
Mar 07 '24 |
Sale |
76.98 |
10,400 |
800,627 |
43,097 |
Hippel James | CFO |
Dec 19 '23 |
Option Exercise |
31.26 |
47,289 |
1,478,254 |
104,850 |
Nusse Roeland | Director |
Aug 30 '23 |
Option Exercise |
22.40 |
32,000 |
716,800 |
60,811 |
Nusse Roeland | Director |
Aug 30 '23 |
Sale |
80.32 |
8,939 |
717,959 |
51,872 |
Kelderman Kim | Pres. Diagnostics & Genom |
Aug 24 '23 |
Option Exercise |
47.60 |
2,100 |
99,960 |
21,225 |
Kummeth Charles R. | Chief Executive Officer |
Aug 15 '23 |
Option Exercise |
0.00 |
17,632 |
0 |
1,286,944 |
Kummeth Charles R. | Chief Executive Officer |
Aug 05 '23 |
Option Exercise |
0.00 |
51,516 |
0 |
1,310,282 |
Hippel James | CFO |
Aug 05 '23 |
Option Exercise |
0.00 |
12,876 |
0 |
63,896 |
Kelderman Kim | Pres. Diagnostics & Genom |
Aug 05 '23 |
Option Exercise |
0.00 |
8,060 |
0 |
23,264 |
Kummeth Charles R. | Chief Executive Officer |
Jul 21 '23 |
Sale |
88.36 |
80,000 |
7,069,024 |
1,258,766 |
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Cap:
|
Volume (24h):